Fig. 7: TEAD4 could be a potential target for cancer therapy.

a TEAD4 expression in Oncomine (www.oncomine.org) Taylor prostate cancer database (n for normal = 29, n for cancer = 131, the center line indicates median, ****p < 0.0001). b Association of TEAD4 expression with Gleason score in Oncomine (www.oncomine.org) Taylor prostate cancer database (n for normal = 25, n for Grade 6 = 41, n for Grade 7 = 74, n for Grade 8 = 8, n for Grade 9 = 7, the center line indicates the median, *p < 0.05, **p < 0.01, ***p < 0.001). c Correlation of TEAD4 expression with tumor recurrence in Oncomine (www.oncomine.org) Taylor prostate cancer database (n for no recurrence = 3, n for recurrence at first year = 9, n for recurrence at third year = 11, n for recurrence at fifth year = 3, whiskers = min to max, bounds of box = lower quartile and upper quartile, the center line indicates the median, *p < 0.05, **p < 0.01). d Kaplan–Meier survival plot shows the correlation of TEAD4 expression with survival rate in Oncomine (www.oncomine.org) Setlur prostate cancer database (n for low expression = 243, n for high expression = 119). e TEAD4 expression in immortalized prostate cell line, RWPE1, and prostate cancer cell lines, CWR22Rv1, PC3, DU145, LNCaP, and C4-2B. f 1 × 10⁵ of scrambled shTEAD4 cells were plated in 24-well plate. Cell growth after silencing of TEAD4 by shRNA in CWR22Rv1 cells. g Doubling time after silencing of TEAD4 by shRNA in CWR22Rv1 cells. h Tumor growth curve of silencing of TEAD4 by shRNA in CWR22Rv1 cells and tumor image by IVIS scan at endpoint. i Isolated tumor image and weight at endpoint. j Tumor growth curve of knockout of TEAD4 by CRISPR-Cas9 in CWR22Rv1 cells and tumor image at endpoint. k Isolated tumor image and weight at endpoint. Data are presented as mean value ± SEM of independent experiments (n = 3 in f, n = 6 in h–k). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, using unpaired two-tailed Student’s t test. Source data are provided as a Source data file.